Randomised controlled trial of mesalazine in IBS

Gut24.50
Volume: 65, Issue: 1, Pages: 82 - 90
Published: Jan 1, 2016
Abstract
Objective Low-grade intestinal inflammation plays a role in the pathophysiology of IBS. In this trial, we aimed at evaluating the efficacy and safety of mesalazine in patients with IBS. Design We conducted a phase 3, multicentre, tertiary setting, randomised, double-blind, placebo-controlled trial in patients with Rome III confirmed IBS. Patients were randomly assigned to either mesalazine, 800 mg, or placebo, three times daily for 12 weeks, and...
Paper Details
Title
Randomised controlled trial of mesalazine in IBS
Published Date
Jan 1, 2016
Journal
Volume
65
Issue
1
Pages
82 - 90
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.